Kirsten L. Bryant - Concepedia

Author

Kirsten L. Bryant

University of North Carolina at Chapel Hill ORCID

Also Known As

Beelen, Andrew P, Bryant, Kirsten L., Chang, Wen-Hsuan, Cox, Adrienne D., Droby, Gaith N., Edwards, A. Cole, Hu, Chaoxin, Huntsman, Emily M, Jennifer E. Klomp, Kirsten Bryant

198

Publications

3.5K

Citations

H-Index

Concepts

All Affiliations

University of North Carolina at Chapel Hill George Mason University Cornell University Translational Genomics Research Institute University of Helsinki

About

Kirsten L. Bryant is an author at University of North Carolina at Chapel Hill specializing in medicine, cell biology, and cell signaling.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	1.7K
2	Cell Biology	6	6	1K
3	Cellular Physiology	3	3	230
4	Biochemistry	2	2	207
5	Natural Sciences	1	1	186

Kirsten L. Bryant

Publications

2.4K

Citations

H-Index

Page 1

	Year	Citations
Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer Kirsten L. Bryant, Clint A. Stalnecker, Daniel Zeitouni, Nature Medicine Tumor BiologyCell AutophagyPancreatic CancerMedicineAutophagy	2019	695
Cancer cell-derived microvesicles induce transformation by transferring tissue transglutaminase and fibronectin to recipient cells Marc A. Antonyak, Bo Li, Lindsey K. Boroughs, Proceedings of the National Academy of Sciences Extracellular MicrovesiclesHorizontal TransferCancer BiologyGliomaTumor Biology	2011	489
Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression Tikvah K. Hayes, Nicole F. Neel, Chaoxin Hu, Cancer Cell OncologyPancreatic CancerLong-term Erk InhibitionMedicineSenescence-like Growth Suppression	2015	271
Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer G. Aaron Hobbs, Nicole M. Baker, Anne M. Miermont, Cancer Discovery	2019	210
KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism Angelina V. Vaseva, Devon R. Blake, Thomas S.K. Gilbert, Cancer Cell Reductive StressSignal TransductionBiochemistryNatural SciencesReceptor Tyrosine Kinase	2018	186
Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i> Mutant Pancreatic Cancer Craig M. Goodwin, Andrew M. Waters, Jennifer E. Klomp, Cancer Research	2022	144
The Sustained Induction of c-MYC Drives Nab-Paclitaxel Resistance in Primary Pancreatic Ductal Carcinoma Cells Erika Parasido, George Avetian, Aisha Naeem, Molecular Cancer Research	2019	83
Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancer Jennifer E. Klomp, J. Nathaniel Diehl, Jeffrey A. Klomp, Science	2024	69
KRAS-dependent cancer cells promote survival by producing exosomes enriched in Survivin Wen-Hsuan Chang, Thuy‐Tien T. Nguyen, Chia‐Hsin Hsu, Cancer Letters	2021	45
CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment Jennifer E. Klomp, Ye S. Lee, Craig M. Goodwin, Cell Reports Cancer ResearchOncogenic Kras-expressing CellsDna DamagePancreatic CancerCell Regulation	2021	40

Page 1